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Abstract: Acquired resistance is one of the major barriers to successful cancer therapy. The
development of resistance is commonly attributed to genetic heterogeneity. However, heterogene-
ity of drug penetration of the tumor microenvironment both on the microscopic level within solid
tumors as well as on the macroscopic level across metastases may also contribute to acquired drug
resistance. Here we use mathematical models to investigate the effect of drug heterogeneity on the
probability of escape from treatment and time to resistance. Specifically we address scenarios with
sufficiently efficient therapies that suppress growth of all preexisting genetic variants in the com-
partment with highest drug concentration. To study the joint effect of drug heterogeneity, growth
rate, and evolution of resistance we analyze a multitype stochastic branching process describing
growth of cancer cells in two compartments with different drug concentration and limited migra-
tion between compartments. We show that resistance is more likely to arise first in the low drug
compartment and from there populate the high drug compartment. Moreover, we show that only
below a threshold rate of cell migration does spatial heterogeneity accelerate resistance evolution,
otherwise deterring drug resistance with excessively high migration rates. Our results provide new
insights into understanding why cancers tend to quickly become resistant, and that cell migration
and the presence of sanctuary sites with little drug exposure are essential to this end.
Key words: tumor microenvironment, spatial drug gradient, evolutionary rescue, branching
process, metastasis
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Author Summary: Failure of cancer therapy is commonly attributed to the outgrowth of
pre-existing resistant mutants already present prior to treatment, yet there is increasing evidence
that the tumor microenvironment influences cell sensitivity to drugs and thus mediates the evo-
lution of resistance during treatment. Here, we take into consideration important aspects of the
tumor microenvironment, including spatial drug gradients and differential rates of cell prolifera-
tion. We show that the dependence of fitness on space together with cell migration facilitates the
emergence of acquired resistance. Our analysis indicates that resistant cells that are selected for
in compartments with high concentrations are likely to disseminate from sanctuary sites where
they first acquire resistance preceding migration. The results suggest that it would be helpful to
improve clinical outcomes by combining targeted therapy with anti-metastatic treatment aimed at
constraining cell motility as well as by enhancing drug transportation and distribution throughout
all metastatic compartments.
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I. INTRODUCTION
Cancer is a common genetic disease that results from accumulated (epi-)genetic changes in
tumor cells [1–5]. Targeted cancer therapy is currently an area of active research [6], and is under
rapid development [7–10]. Targeted agents can send cancer into remission, but the response is
often short-lived [7–11]. The recurrence of cancer, if treated with single agents, is almost certain
due to acquired drug resistance [12, 13]. Among efforts to understand the rapid acquisition of
resistance by cancer cells, particular attention has been paid to the pre-existing resistance arising
prior to treatment [14–17].
In parallel, there has been growing interest in studying how the tumor microenvironment influ-
ences cell sensitivity to drugs and thus mediates the evolution of resistance during treatment [19–
24]. Important aspects of the tumor microenvironment include spatial drug gradients and dif-
ferential rates of cell proliferation [23, 24]. The heterogeneity of this kind can be found both
on the microscopic level within solid tumors as well as on the macroscopic level across metas-
tases [21, 23, 24]. It is not uncommon that incomplete drug distributions within and across
metastatic lesions can compromise the efficacy of treatment [23, 24], which may be in part due
to the differences in the ability of the drug to penetrate different tissues [25]. As shown in recent
experimental and theoretical studies [26–29], drug gradients can help accelerate the evolution of
antibiotic resistance. When it comes to anticancer treatment, the consequences of spatial hetero-
geneity in drug concentrations on the emergence of resistance have yet to be fully addressed.
Amounting evidence suggests metastasis, at least for some cancers, is an early event during
primary tumor development [19, 30–35]. By activating tissue invasion and metastases [36], cancer
cells are able to escape from the primary site and disseminate to distant parts of the body, causing
life-threatening health problems [37, 38]. At the time of diagnosis and treatment (which generally
occur late in the course of disease), a high proportion of common cancer patients have already had
tumor cells disseminated to distant sites for years prior to presentation [30, 42]. What is more,
clinical outcomes are often complicated by the presence of overt or occult micrometastases in
patients [30, 39–42]. It is, therefore, of primary interest to understand the emergence of resistance,
particularly in the setting of disseminated cancer.
A recent study reported that circulating tumor cells are detected in 13 out of 36 breast cancer
survivors 7-22 years after receiving mastectomy [43]. This observation suggests that dissemi-
nated cancer, rather than only the primary tumor in situ, is actually under stress when treatment is
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started [30, 40, 42]. Moreover, a few studies observed that metastatic cells tend to quickly become
chemoresistant [22, 44–49], suggesting a positive relationship between metastatic phenotype and
the rapid acquisition of drug resistance. It is possible that, with the migration and seeding dy-
namics [31, 34, 42, 50–53], these metastatic cells located at distant metastatic compartments can
re-seed each other, particularly in the presence of tumor sanctuary sites with very little drug expo-
sure. Therefore, it is necessary to explicitly account for the role that the metapopulation structure
of metastatic disease plays in the rapid emergence of resistance.
Most recently, in an in vitro experiment with metastatic breast cancer cells [54], it was shown
that cell motility and drug gradient of chemotherapy together can lead to fast emerging resistant
cells in areas of high concentrations that would otherwise completely inhibit cell growth. This
important experimental result begs theoretical questions aimed at revealing the relevant pathways
of evolving resistance. Do tumor cells first migrate from low concentration areas and then adapt
to high concentration areas? Or alternatively, do they first acquire resistance in low concentra-
tion areas and then migrate to and populate areas of exceedingly high concentrations? How do
cell motility and drug gradient, or more generally how does the spatial heterogeneity in drug con-
centrations affect the emergence of resistance? The goal of the present work is to answer these
questions and provide qualitative insights by a simple conceptual model.
Here we focus on the macroscopic level of the tumor microenvironment across metastases, ex-
plicitly taking into account the roles of the multi-compartment structure of metastases and cell
migration in the emergence of acquired resistance during treatment. Spatial compartments mean
different locations that harbor metastatic deposits (i.e., target organs, such as bone marrow, liver,
brain and lung) [34]; migration means dissemination and seeding of cells between metastatic com-
partments [35]. We focus on the common population dynamics that govern the evolution of re-
sistance for various cancers differing in their capacity to metastasize. Metastases of solid tumors
(such as breast cancer [41] and melanoma [10]) tend to have well-defined spatial compartments
because of low dissemination rate, whereas the compartment structure of liquid cancer (e.g. blood
tumors [7]) is diminished by exceedingly high fluidity. By adjusting the migration rate, our model
can be suited to study the specific kind of cancer in question.
Clinical observations from multiple sources affirm that an exponential growth model, although
remaining an issue of debate [55], is able to adequately describe tumor growth for most cancer
patients [56–62]. In line with this, we use a stochastic, multi-type branching model to account
for the fate of individual cells, particularly these drug-resistant mutations in establishing surviv-
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ing lineages. Mathematical models of this kind have provided particularly useful insights into
understanding evolutionary dynamics of cancer in response to treatment [11, 14–18, 63–65] (see
a review in Ref. [66]). A large set of previous models are focused on pre-existing resistance in
the primary tumor, arising from neutral evolution prior to treatment [15, 17]. Built on these prior
studies, the current work incorporates the compartment structure of metastatic disease and quan-
tifies the role spatial heterogeneity in drug concentrations plays in the evolution of resistance by
metastatic cells during treatment.
In our model, cancer cells can migrate from one spatial compartment to another. Spatial hetero-
geneity in drug concentrations means that there exist sanctuary sites that are not or only partially
penetrated by drugs. Therefore, reproductive fitnesses of cells depend not only on their cell types
but also on their spatial locations, leading to a rugged fitness landscape (since drug concentra-
tions in different spatial compartments are not necessarily continuous but discrete in space). As
shown in previous studies [11, 14, 15], if the fitness of resistant cells as compared to sensitive
cells is neutral or even slightly advantageous in the absence of drugs, the acquisition of resistance
not only becomes highly likely but also is accelerated, since there is no selection pressure against
resistance. However, it is less clear about the most likely pathway to select for resistance, if re-
sistance mutations incur a fitness cost in the absence of drugs while conferring an advantage over
sensitive cells in the presence of drugs. Recent mathematical modeling with laboratory test using
mice suggests that resistance carries a fitness cost [67]. In view of this, the present study is fo-
cused on the latter scenario with fitness cost of resistance, although our approach works for any
fitness landscape. We show that resistant mutants are unlikely to emerge in situ in compartments
of high drug concentrations, but arise through the mutation-migration pathway; namely, metastatic
cells acquire costly resistance in the sanctuary sites preceding migrating to and thriving in harsh
compartments containing high levels of drugs.
II. RESULTS
Without loss of generality, let us first study the simplest possible ‘drug-sanctuary’ scenario
for treatment failure due to imperfect drug penetration, as illustrated in Fig. 1. We consider two
spatial compartments with dichotomic distributions of drugs: compartment ‘0’ can hardly be pen-
etrated by the cancer drug, thereby representing a perfect drug sanctuary site; compartment ‘1’
is distributed with adequate amount of drugs that are able to completely wipe out all wild type
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cells. We assume that one point mutation is sufficient to confer high levels of resistance to the
maximum possible concentration of drugs administered during therapy. We denote the genotypes
of cells by the number of acquired point mutations: the wild type ‘0’ and the resistant type ‘1’
(see Materials & Methods for a detailed description of the model). This minimal model, albeit
overly simplified, offers intuitive insights into understanding how spatial drug heterogeneity fa-
cilitates the acquisition of de novo resistance during cancer therapies. Later on, we will extend
this simple model to more realistic cases with multiple cell types and with multiple compartments,
where multiple point mutations can successively accrue to confer resistance to exceedingly high
drug concentrations [54].
In the presence of a sanctuary compartment, there exist two competing pathways to lead to the
outgrowth of resistance in the compartment of high drug concentrations, as depicted in Figs. 1b
and 1c. One is the “migration-mutation” pathway: sensitive cells first emigrate from the sanctuary
compartment and then adapt in situ to the non-sanctuary compartment with high drug concen-
trations. The other is the “mutation-migration” pathway: sensitive cells first mutate and acquire
resistance in the sanctuary compartment, and then migrate to and populate the compartment with
high drug concentrations. To understand how the presence of tumor sanctuary sites and cell mi-
gration together affect the resistance evolution, we need to determine which pathway provides the
more likely path to resistance.
Because cells of the same types have different fitness in the two compartments, we regard mi-
gration as a sort of status change in spatial locations. In this way, the two competing pathways
can be seen as three-type branching processes, respectively, with different fitness landscapes. Our
results are based on multi-type branching processes (Figs. 1b and 1c) [17, 64, 69–71] (see deriva-
tion details in the supplementary information). To make progress, let us assume the following
rugged fitness landscape owing to the heterogeneity of drug distributions across compartments.
In the sanctuary compartment 0, both sensitive and resistant cells have supercritical replication
potential, but resistant cells have slightly lower replication rates than sensitive type due to the cost
of the resistant mutation; that is, b00 > d00, b10 > d10, and b10 < b00. In the drug compartment 1,
sensitive cells have a subcritical replication potential while resistant cells still have a supercritical
replication potential; that is, b01 < d01, b11 > d11, and b11 > b01.
Although our method works for any mutation rate and migration rate (see Materials & Meth-
ods), we find a simple condition in the limit of low rates of mutation and migration (Fig. 2). (Such
limiting results should hold true in realistic settings of cancer dynamics, given that the point mu-
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tation rate of most cancers is estimated to be 10−8 ∼ 10−9 [1, 2] and the dissemination rate of
pancreatic cancer cells ∼ 10−7 [72].) That is, the mutation-migration pathway is faster than the
counterpart, the migration-mutation pathway, to result in resistance in the drug-containing com-
partment, if the fitness landscape satisfies the following inequality:
b00
b00 − d00 − (b10 − d10) >
b01
b00 − d00 − (b01 − d01) . (1)
Since most targeted therapies have cytostatic effects, other than the cytotoxic effects commonly
seen in traditional chemotherapy [68], in this work we assume the drug inhibits cell proliferation
and does not affect death rates of cells. The condition above can be greatly simplified when the
two compartments provide exactly the same condition for population outgrowth in the absence of
drugs. The rugged fitness landscape due to spatial drug heterogeneity, therefore, can be reflected
solely by differences in proliferation rates (i.e., d00 = d10 = d01 = d11). Moreover, the fitness cost
of resistance, s, for resistant cells located in the sanctuary compartment 0 can be parameterised as
b10 = (1 − s)b00, while the fitness cost of sensitivity, δ, for wild type cells in the drug-containing
compartment 1, b01 = (1 − δ)b00. Substituting these parameterizations into (1), we arrive at the
much simplified condition in terms of s and δ:
δ >
s
1 + s
. (2)
We immediately observe that this condition is expected to be fulfilled in most cases since potent
therapy should be characterized by δ > s.
Our mathematical framework allows us to calculate the probability of no resistance with respect
to time, conditional on non-extinction and starting with a single sensitive cell following each
pathway separately (Figure 2a). We also calculate and compare the average time to resistance
(relapse time conditional on non-extinction) following each pathway, as shown in Fig. 2b. The
result demonstrates that the simple condition as given in Eq. (2) works well in the limit of low
migration rate and remains a good approximation for intermediate migration rates. Moreover, if
resistant mutation is neutral or even advantageous in the sanctuary, then the mutation-migration
pathway is always much faster than the migration-mutation pathway to result in resistance in the
drug-containing compartment (Fig. 2c).
Another important aspect of tumor microenvironment is characterized by differential rates of
proliferation across compartments in the absence of treatment: cells in the sanctuary compartment
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may have slower replication and turnover rates than these in other compartments [23]. We thus
use the parameter 0 < φ ≤ 1 to rescale the proliferation and death rates of cells in the sanctuary
compartment 0 relative to that in the drug-containing compartment 1: d00/φ = d10/φ = d01 and
b01 = (1 − δ)b00/φ (which implies that in the absence of treatment, cells grow 1/φ times as fast
in compartment 1 as when located in compartment 0). Although one should refer to the general
inequality (1) as the exact condition for the mutation-migration pathway to be predominant, simple
algebra shows that the simplified inequality (2) is still a necessary condition in this case. In fact,
reducing the rate of cell proliferation in the sanctuary equally affects the two pathways, delaying
the time to resistance (Fig. 2d). Taken togethers, these results demonstrate that, under a wide
variety of conditions (including the ranges of parameter values relevant to cancer), prevailing
resistant cells in compartments with high levels of drugs are likely to originate from sanctuary
sites, where they acquired resistance preceding migration.
Of interest is to observe the evolutionary process initiated by a single sensitive cell located
in the compartment of high drug concentration. We develop a numerical method to show the
spatio-temporal dynamics of emerging drug resistance across spatial compartments (see Materials
& Methods). Note that different from the constrained pathways analyzed in Fig. 2, in this case, mi-
gration is allowed to be bi-directional, and both pathways can be at work at the same time. Doing
this enables us to study the emergence of resistance in a more natural and realistic setting. Figure
3 shows the joint probability distribution of the numbers of resistant cells in the two compartments
with respect to time. The skewed distribution in Fig. 3a suggests that the sanctuary compartment
provides much more favorable condition to evolve resistance than the drug-containing compart-
ment, and thus escaping from the drug-containing compartment to the sanctuary compartment
is crucial to this end. Constantly seeding the drug-containing compartment with evolved resistant
cells tends to make the distribution more balanced (cf Figs. 3b and 3c). As a result, resistance soon
gets established in the drug-containing compartment, and its growth outpaces that in the sanctu-
ary compartment (Fig. 3d ), although the chance of having resistance increases steadily with time
in both compartments. Similar results are obtained using different initial conditions, despite that
resistance evolution is more likely (and sooner) to occur when the sensitive cell is initially placed
in the sanctuary compartment than in the drug-containing compartment (cf. Fig. S1 and Fig. 2).
Our results demonstrate that the sanctuary compartment, even though cells are slowly replicating
therein, serves as an escape hatch, and indeed is most likely to be the breeding ground of resis-
tance. Therefore, in the presence of sanctuary sites, the overwhelming outgrowth of resistance in
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the drug-containing compartment is an inevitable outcome due to the mutation-migration pathway.
Having illuminated the essence of the problem (Figs. 1-3), we now turn to predict outcomes
of hypothetical treatments to eradicate (two) metastases in cancer patients (Fig. 4). We assume
the total mass of metastasis is relatively small so that treatment starts without any pre-existing
resistance. In particular, we assume that the two metastatic lesions differ in size as well as in
the level of drug penetration, because of different microenvironments. Specifically, cells in lesion
0 grow much more slowly than in lesion 1 in the absence of drugs, yet the drugs have better
penetration of lesion 1 than of lesion 0. To this end, we continuously vary the difference of
drug concentrations in the two compartments, ∆D = D1 − D0, while keeping the total sum of
concentrations constant. Let us now specifically incorporate into the simple model a Hill function
that describes concentration-dependent killing efficacy of drugs (see Materials & Methods).
Without migration and under homogeneous drug concentrations the metastatic cancer almost
certainly can be eradicated successfully. However, a worrying situation arises in the presence of a
sanctuary with sufficiently low drug concentrations. With increasing difference of drug concentra-
tion between the two metastatic compartments, treatment responses exhibit a sharp transition from
successful eradication to failed treatment due to acquired resistance (Fig. 4a). Our mathematical
framework allows us to calculate the relapse curve, 1 − ps(t), where ps(t) is the probability of no
resistance by time t following treatment, and the (conditional) average time to patient relapse due
to acquired resistance (see Materials & Methods). Figure 4b shows that the relapse is accelerated
by the spatial heterogeneity; the larger ∆D, the faster the relapse. In this simulated hypothetical
patient with small lesions, the worst-case scenario is when the drug cannot penetrate lesion 0 at all,
and thus the relapse occurs on average approximately 103 days. The relapse could have occurred
within weeks if the treatment starts with much bigger lesions (Fig. S2).
Especially when cells can migrate, resistance results not only from cells originally in the
metastatic compartment 0 but also from these escaping from compartment 1 . Noteworthy, cell
lineages originating from lesion 1 are faster to evolve resistance than these originating from lesion
0 (Fig. 4b). This result is mainly due to the initial condition used: lesion 1 is much larger than
lesion 0 that the influx of escaping cells to the sanctuary exceeds the number of cells in situ. Since
we are considering a branching process, larger population size is more likely to generate resistant
mutation. Indeed, as shown in Fig. S2, if the size of lesion 1 is smaller, cells lineages originating
from lesion 1 are actually slower to evolve resistance than from lesion 0.
We emphasize that the monotonic decreasing relationship of relapse time with increasing the
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drug concentration difference, ∆D, is due to: (1) one point mutation is sufficient to confer strong
resistance to the maximum possible concentration in compartment 1 (D1 = 100) in this simulated
case; (2) compartment 0, which is distributed with less and less amount of drugs with increasing
∆D, provides an increasingly favourable condition for the evolution of resistance and thus renders
shorter relapse time, since the mutation-migration pathway is the most contingent pathway for
resistance evolution as shown before. Under different assumptions of fitness effects of mutations
as described in Eq. (A1), however, multiple point mutations might be required to confer sufficient
level of resistance to increasingly high concentrations in compartment 1 , as ∆D increases. This
variation does not change the general picture about how the presence of sanctuary sites impairs
the effectiveness of cancer therapies (Fig. S4a), but the time to sufficient level of resistance may
well depend on how many point mutations are needed to this end and exhibits an abrupt increase
when ∆D is increased beyond a critical threshold value (the vertical line in Fig. S4b). For very
large ∆D, only two-point mutants are able to survive in compartment 1, wherein the abundances
of one-point mutants and sensitive cells are maintained by the immigration-death equilibrium of
the branching process. As time passes by, two-point mutants eventually pop up, most likely in the
sanctuary compartment 0, and subsequently immigrate to and populate the compartment 1.
Taken together, Fig. 4 demonstrates that metapopulation dynamics arising from migration and
seeding, together with the presence of sanctuary sites, play an important role in the rapid emer-
gence of resistance. Furthermore, only for migration rates below a certain critical threshold does
the spatial heterogeneity in drug concentrations speed up the emergence of resistance. Excessively
high migration rates actually slow down resistance emergence (Fig. S3), as the role of compart-
ment structure is diminished by frequent migration and consequently cells are exposed to the drug
compartment more often. It is worth noting that there exists an optimum migration rate that leads
to the fastest emergence of resistance and that excessively high migration rates actually deter and
delay the evolution of resistance (Fig. S3). The results suggest that it may be helpful to improve
clinical outcomes by combining targeted therapy with anti-metastatic treatment aimed at inhibiting
cell motility as well as by enhancing drug transportation and distribution throughout all metastatic
compartments.
We also extend the simple model to more general cases with multiple cell types and with mul-
tiple compartments (see detailed mathematical description in the SI). In this extended model, mul-
tiple point mutations can consecutively accrue to confer resistance to increasingly high drug con-
centrations. In particular, we study and compare the impact of the two different schemes of cell
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migration, local versus global migration, on the evolution of resistance (Figs. S5 and S6). The
numerical results confirm that our conclusions derived from the simple model above remain qual-
itatively unchanged. Additionally, we observe that strong resistance evolves much faster for local
migration than global migration, particularly for sensitive cells located at the sanctuary sites with
low drug concentrations (Fig. S5). In other words, sequential local migration over spatial gradient
of drug concentration following newly accrued point mutations (i.e., the mutation-migration path-
way) plays an important part in leading to rapid selection for high-level resistance. This may be
of particular relevance for the evolution of resistance within a solid tumor [23, 54]. Furthermore,
apart from oversimplified migration schemes addressed in the current study, this full model can be
readily extend to integrate with a realistic vascular network that regulates the metastatic routes of
circulating tumor cells among target organs [53].
Last but not least, let us demonstrate how the evolution of resistance can be facilitated by
the microenvironment within a tumor on the microscopic level [23]. Specifically, we consider a
solid tumor consisting of 1011 cells which is about 4.6 cm in diameter [57]. Figure 5a shows the
schematic representation of tumor microenvironment of cells surrounding a blood vessel located
in the centre: the rate of proliferation of tumor cells decreases with increasing distance from
the central blood vessel in the absence of treatment. Similarly, the delivery of cancer drugs is
also compromised in the presence of treatment, thereby resulting in the spatial drug gradient as
illustrated in Fig. 5b. The level of spatial drug heterogeneity is represented by 1/τD: the larger of
this value, the more poorly the drug penetrates distal tumor issues away from the nearest blood
vessel. To make progress in our calculations, we artificially divide the tumor into M = 30 spatial
compartments with consecutive concentric circles with equal interval in between from centre to
surface. We confirm that dividing more compartments leads to almost the same results as shown
here in Figs. 5c and 5d. In this simulated example, two point mutations are required to confer full
resistance to the maximum drug concentration in the centre. As shown in Fig. 5c, the tumor can
be eradicated under perfect drug penetration where the drug is almost homogeneously distributed
throughout the entire tumor population (extremely small 1/τD). In contrast, inadequate penetration
of the tumor gives rise to sanctuary sites, these outer compartments that are most distant away from
the blood vessel and thus exposed with the least amount of drugs. Therefore, cancer therapy fails
certainly with large values of 1/τD. In line with Fig. 4, relapse occurs sooner with increasing
spatial drug heterogeneity, 1/τD (Figs. 5d). Moreover, distal cells, although slowly proliferating,
are more likely to generate resistance than these proximal cells that are affected most by the drug.
12
These results quantitatively demonstrate that tumor microenvironment mediates cell sensitivity to
drugs and thus plays an important role in drug resistance acquired during treatments[23, 54].
III. DISCUSSION
Here we study the roles that cell motility and spatial heterogeneity in drug concentrations play
in the emergence of acquired resistance to cancer therapy. Cancer cells can migrate from one
spatial compartment to another. As compartments may contain different levels of drugs, the cells
experience distinct selection pressure for resistance in different compartments. We calculate the
probability of resistance and the average time to resistance for sensitive cells originally located
in different compartments. We show that the presence of sanctuary sites with poor drug penetra-
tion can speed up the emergence of acquired resistance to cancer therapy. Moreover, we show
that resistance is unlikely to arise in situ within high concentration compartments, but rather that
resistance first emerges in sanctuary sites and then spreads to and populates other compartments
with high concentrations that would be able to completely inhibit growth of sensitive cells. This
result is in line with a prior analysis of competing pathways to resistance, based on an ecological
source-sink model with logistic population growth [73]. In spite of that, our study is specifically
aimed at understanding the role of tumor microenvironment in the evolution of resistance during
treatment. More important, the current work can be used to interpret recent experimental results
demonstrating that cell motility and drug gradients can facilitate the emergence of resistance [54].
Previous studies both empirically and theoretically reveal that spatial drug gradient can facili-
tate the evolution of antibiotic resistance [26–29]. Although well suited for studying experimental
microbial evolution [27, 28], these models are not directly applicable to the context of cancer;
especially solid tumours with intrinsic heterogeneity in their microenvironments warrant a thor-
ough separate investigation [19–21]. Furthermore, in these prior models [27, 28], compartments
are placed in an order with increasing drug concentration, sequential migration occurs only be-
tween the two nearest neighbor compartments, and evolution begins within the sanctuary while
other compartments are initially void. In contrast, the present mathematical framework takes into
account realistic concentration-dependent response for any initial population of cancer cells dis-
tributed over multiple metastatic compartments, and allows us to calculate the risk of acquiring re-
sistance as well as to ascertain the timing of relapse. Moreover, our model can be readily extended
to incorporate specific migration schemes of cancer cells, e.g., along with a more realistically
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connected vasculature [53]. In parallel, it is worth mentioning that the approach of using partial
differential equations to describe spatio-temporal dynamics of cancer evolution [89–91] sheds a
different yet useful insight on the selection of resistance under cancer therapies [92, 93]. Taken
together, our theoretical results improve our understanding of how metastatic cells can acquire
resistance during treatment, especially in the presence of sanctuary sites.
In this study we focus on the evolution of resistance exclusively in the population of metastatic
cells that have the same capacity to migrate. It has been shown that migratory cells, though with
lower growth potential than non-migratory cells, can be selected for during therapy [94]. Extend-
ing this prior result, our results show that cell motility and the presence of sanctuary sites with little
drug exposure are essential for the rapid acquisition of resistance by metastatic cells. Moreover,
only for low migration rates below a certain threshold does spatial heterogeneity in drug concen-
tration speed up resistance evolution. Arguably, this finding may help to explain qualitatively the
differences of clinical successes in treating liquid cancer (such as chronic myeloid leukemia [7])
and solid tumors (such as melanoma [10]). Because of limited cell motility, metastases of solid
tumor tend to have well-defined spatial compartments (namely, distal lesions), and thus are more
prone to drug penetration problems. For this reason, additional attention should be paid to elimi-
nate the sanctuary sites for cancer therapy [22].
In the current work, we only consider resistance to a single drug, or, to be more precise to treat-
ment with a drug or drug combination to which resistance can be generated by a single mutational
event. It is promising for future work to study multi-drug resistance requiring multiple resistance
mutations, given that combination therapy is increasingly used in clinical setting [74, 75]. In ad-
dition to the spatial heterogeneity in drug concentrations addressed here, we think that epistatic
interactions of resistant mutations to each drug may also be important and deserve further investi-
gation [76].
Our results suggest that combining targeted therapy with anti-metastatic treatment might help
improve clinical outcomes [77–79], especially when treating disseminated cancer. As demon-
strated in the present work, inhibition of cell migration between compartments not only suppresses
the escape route of sensitive metastatic cells to sanctuary sites and also prevents the dissemination
of evolved metastatic cells from sanctuary sites to these compartments with high concentrations,
where resistance is strongly selected for. Furthermore, it is desirable to enhance drug transporta-
tion and distribution throughout all metastatic compartments, in order to deter the rise of resistance.
The current model is minimalistic, but allows proof of principle. We leave out many important
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issues, such as cancer stem cells [80–83], cellular quiescence and cancer dormancy [84, 85], and
the inefficiency of metastatic processes [86–88]. In particular, we have considered the dynamics
of the evolution of drug resistance in a situation in which cells are able to move freely from one
compartment (tumor) to another. This first approximation, while enlightening, may overestimate
some of the dynamics that would occur in a more realistically connected vasculature, especially
when the inefficiencies of metastasis, due to filtration and dissemination in the vascular network,
are considered [52, 53]. With the increasing understanding of the molecular biology of metas-
tasis as well as clinical advances in treating metastasis, we believe that it will become feasible
to obtain accurate estimations of key parameters regarding metastatic burden (location and size)
and metastatic rates. Then a calibrated model of this sort as introduced here can be used to sim-
ulate patient responses in silico and predict outcomes of treatments to eradicate the disseminated
cancer [11].
IV. MATERIALS & METHODS
a. Minimal model. We focus the present study on the role that tumor microenvironment
plays in the emergence of acquired resistance to potent cancer therapies, where de novo mutations
are required to confer strong resistance to high drug concentrations. In our model, we explicitly
account for the compartment structure of tumor microenvironment as well as the spatial hetero-
geneity in drug concentrations across compartments. For proof of concept, we focus on the sim-
plest possible case with only two compartments and two types of cells in the main text. Without
loss of generality, we assume that drugs have better access to compartment 1 than to compartment
0. In contrast to conventional chemotherapy agents that have cytotoxic effects, most molecularly
targeted cancer therapies have cytostatic effects on cancer cells [68]. Moreover, it is commonly
found that the efficacy of drugs is concentration-dependent in pharmacological kinetics studies
ranging from antimicrobial treatment to cancer therapy [95–98]. Therefore, it is plausible for us to
specifically consider concentration-dependent inhibition of cell replication in response to cancer
therapy.
Denote by Di the drug concentration in compartment i. Upon division, one of the daughter
cells can mutate with probability u to become resistant. Denote by i the genotype of a cancer cell
if it has acquired i point mutations (i = 0, 1). The fitness of a cell depends on its type and spatial
location. Specifically, the replication rate of a cancer cell, bi j, is determined by its genotype i and
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spatial location j ( j = 0, 1) as follows,
bi j = β j
1 − is
1 +
[ D j
ρiIC50
]m . (3)
Here we use a Hill function for the drug response curve [99]. β j (α j, respectively) is the division
rate (the death rate, respectively) of a sensitive cell located in compartment j in the absence of
drugs, s is the cost of resistance mutation in the absence of drugs, IC50 is the drug concentration
that is needed to inhibit cell growth by one half of its original rate, ρ is the fold increase in IC50
per mutation, and m determines the steepness of the Hill function. Previous studies have fitted
empirical data to similar Hill functions as given above (Eq. (A1)), to indicate antibiotic resistance
and antiviral resistance to various treatment regimens [95, 99]. Although a full characterization
of cancer drug resistance in this way has yet to be done, our general results are not dependent
on specific parameter choices of s, ρ, m and IC50. The death rate of a cell with genotype i and in
compartment j is unaffected by the presence of drugs and equal to that of sensitive cells irrespective
of their genotypes, di j = α j. The net growth rate is denoted by ri j = bi j − di j. Cells can migrate
between the two compartments with rate v. The unit of all rates is per cell per day.
b. Generating function approach. Denote by Fi j(X; t) the probability generating function
for the lineages at time t initiated by a single i j-type cell, where X = [x00, x01, x10, x11] denotes
the vector of dummy variables with elements xi j representing each i j-type of cells. The backward
equations for this branching process are (see SI for how to derive them)
∂F00
∂t
= d00 + b00(1 − u)F200 + b00uF00F10 + vF01 − (d00 + b00 + v)F00
∂F01
∂t
= d01 + b01(1 − u)F201 + b01uF01F11 + vF00 − (d01 + b01 + v)F01
∂F10
∂t
= d10 + b10F210 + vF11 − (d10 + b10 + v)F10
∂F11
∂t
= d11 + b11F211 + vF10 − (d11 + b11 + v)F11. (4)
The initial condition is given by Fi j(X; 0) = xi j.
c. Probability of acquired resistance. To extract marginal joint probabilities from generating
functions, we use the Cauchy’s integral method to replace the task of taking multiple derivatives.
Similar methods have been used in the literature [100, 101]. For example, the probability density
of the number of resistant cells, pmn(t) in both compartments at time t, as shown in Fig. 3, is given
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by
pmn(t) = 1
m!
1
n!
∂F01(1, 1, x, y; t)
∂xm∂yn
∣∣∣∣∣
x=0,y=0
.
Using the Cauchy’s integral formula, we obtain
pmn(t) = 1
m!n!
m!n!
(2pii)2
∮
c
∮
c
F01(1, 1, x, y; t)
xm+1yn+1
dxdy
=
1
4pi2
∫ 2pi
0
∫ 2pi
0
F01(1, 1, eiθ1 , eiθ2; t)e−imθ1e−inθ2dθ1dθ2 (5)
Applying the trapezoid rule to approximate the double integral, we arrive at:
pmn(t) ≈ 1N2
N−1∑
i1=0
N−1∑
i2=0
F01(1, 1, eii1 2piN , eii2 2piN ; t)e−imi1 2piN e−ini2 2piN
Note that this formula above is essentially equivalent to the discrete Fourier transform of the
generating function. To reduce the aliasing effect arising from spectral methods, we set N =
1000(≫ 20) for the results presented in Fig. 3.
d. Conditional time to resistance. We use the conditional probability, ps(t), of having no
resistant cells in both compartments to determine the average time to resistance starting with sen-
sitive cells in either compartment. Specifically, starting with a single sensitive cell in compartment
1, the conditional probability ps(t) is given by
ps(t) = F00(1, 1, 0, 0; t)− F00(1, 1, 0, 0;∞)1 − F00(1, 1, 0, 0;∞) . (6)
Then average time to resistance ¯Tr (relapse time) can be calculated as follows,
¯Tr =
∫ ∞
0
ps(τ)dτ. (7)
e. Full model. In the supplementary information, we study more general cases where n
point mutations are needed to confer full resistance and cancer cells can move between M com-
partments with restricted local or unrestricted global migration. Drugs are distributed over M
spatial compartments according to given levels of spatial concentration heterogeneity. In partic-
ular, we consider two different schemes of migration: local migration versus global migration.
Local migration means that compartments are situated on a “ring” where a cancer cell can only
migrate to the two nearest neighbor compartments with equal probability v/2. In contrast, global
migration means compartments are fully connected where a cancer cell is allowed to migrate from
one compartment to any other one with equal probability v/(M − 1). This extended model allows
us to study how metastatic cancer cells acquire increasing levels of drug resistance as they mi-
grate along a spatial gradient of drug concentration and thrive in areas of excessively high drug
concentrations, as shown in a recent in vitro experiment [54].
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Figure legends:
Figure 1 Schematic of the simple model. Here we study the scenarios where drug concentration and the
rate of cell proliferation can be spatially dependent on the tumor microenvironment and de novo
resistance mutations are needed to escape potent treatments (i.e., targeted combination therapies).
(a) Even if only a small number of cells reside in the sanctuary and/or are slowly replicating, they
persistently seed the drug compartment that would have almost certainly become void otherwise.
Therefore, resistance in the drug compartment arises through two competing pathways: (b) the
“migration-mutation” pathway in which sensitive cells first migrate to harsh drug environment and
then evolve resistance in situ, or (c) the “mutation-migration” pathway in which sensitive cells first
acquire the resistant mutation in the sanctuary compartment and then migrate into and subsequently
populate the drug-present compartment. We show that, under a wide variety of conditions, resistant
cells thriving in compartments with high levels of drugs are likely to originate from sanctuary sites,
where they acquired resistance preceding migration.
Figure 2 Competing pathways to selection for resistance. (a) Shown is the probability that no resistant
cells are present at time t, conditional on non-extinction, for the two respective pathways. Circles
are closed-form approximations, and solid lines are obtained by numerically solving the differential
equations of the probability generating functions (see SI for details). In (b), the solid lines show the
average time to resistance (conditional on non-extinction), following the migration-mutation path-
way, as a function of the drug efficacy of growth inhibition of sensitive cells, δ, and with two values
of the migration rate, v. The dashed horizontal lines are the average time to resistance following the
mutation-migration pathway. The vertical line marks the theoretical critical δ = s/(1 + s), above
which the mutation-migration pathway is faster. (c) plots the average time to resistance, following
the mutation-migration pathway, as a function of the fitness cost s of resistance in the absence of
drugs. Resistance mutations are neutral or advantageous for s ≤ 0, while being costly for s > 0.
The horizontal line is the average time to resistance following the migration-mutation pathway. The
dotted vertical line marks the critical s value, expressed in terms of δ, s = δ/(1 − δ). (d) shows
the dependence of the average time to resistance on the relative growth rate r of sensitive cells in
the sanctuary versus in the drug compartment. The scaling parameter r ∈ (0, 1] controls the degree
to which cells in the sanctuary grow slower than in the drug compartment due to the differences in
microenvironment. Reducing the growth rate of cells in the sanctuary prolongs the time to resistance
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and equally affects the two pathways. Parameters: (a – d) b11 = 0.45, d01 = d11 = 0.4, u = 10−4;
(a – c) b00 = 0.5, d00 = d10 = 0.4; (c - d) b01 = 0.35; (a) b01 = 0.39, b10 = 0.48, v = 10−3; (b)
b01 = b00(1 − δ), s = 0.04, v = 10−4, 0.05; (c) b10 = b00(1 − s), v = 10−4; (d) b00 = 0.5φ, d00 = 0.4φ,
s = 0.01, v = 10−3.
Figure 3 Spatio-temporal snapshots of emerging drug resistance. Panels (a) - (d) plot the joint probability
density of the numbers of resistant cells in both compartments at time points t = 10, 50, 100, 200,
respectively, starting with a single sensitive cell placed in the drug compartment. Because the tumor
microenvironment mediates the rate of cell proliferation, we assume that resistant cells grow much
faster in the drug compartment than in the sanctuary compartment. Panels (a) and (b) show that evo-
lution of resistance in situ in the drug compartment is unlikely, and that the sanctuary compartment
provides an escape hatch for sensitive cells originally in the drug compartment to breed resistance.
Panels (c) and (d) show that it becomes increasingly likely that not only resistance gets established in
the drug compartment due to the constant seeding of resistant cells from the sanctuary compartment,
but also its abundance quickly outnumbers that in the sanctuary. Parameters: b00 = 0.1, d00 = 0.05,
b01 = 0.38, d01 = 0.4, b10 = 0.099, d10 = 0.05, b11 = 0.5, d11 = 0.4, u = 10−4, v = 10−2.
Figure 4 Outcomes of in silico treatment to eradicate metastases. The upper row panels (a) show the overall
escape probabilities of the two metastatic lesions (dash-dotted curves), and that of the respective each
lesion (solid curves), with respect to the increasing difference of drug concentration between the two
metastatic compartments, ∆D = D1 − D0, and for varying migration rates, v. Corresponding to
(a), the lower row panels (b) show the average time to resistance (conditional on non-extinction),
as a function of the level of heterogeneity in drug concentrations, ∆D. When treatment starts, a
hypothetical cancer patient has two metastatic lesions: lesion 0 has N0 = 103 cells and lesion 1 has
N1 = 108 cells. We also assume that cells in metastatic compartment 0 (β0 = 0.05, α0 = 0.04)
grow much slower than in compartment 1 (β1 = 0.5, α1 = 0.4), in the absence of drugs. We
assume the drugs have poorer penetration of lesion 0 than of lesion 1, and vary the difference of drug
concentration from 0 (D0 = D1 = 50) to 100 (D0 = 0, D1 = 100). In this simulated case, only
one point mutation is needed to confer strong resistance to high drug concentrations. Parameters:
IC50 = 50, m = 2, ¯D = (D0 + D1)/2 = 50, s = 0.01, ρ = 5, u = 10−9, v = 0, 10−4, 10−3, 10−2.
Figure 5 Tumor microenvironment facilitates the emergence of high levels of drug resistance. For sim-
plicity, we specify the microenvironment of tumor cells in relation to their distance to the nearest
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blood vessel, x. Shown in (a) is the schematic section view of an “onion-structured” solid tumor
with the nearest blood vessel located in the center. In the absence of drugs, both proliferation and
turnover rates of cancer cells decrease with x [23]: birth rate β(x) = b0 exp(−x/τg) and death rate
α(x) = d0 exp(−x/τg), where the parameter τg is the characteristic length scale of spatial decay in
proliferation and turnover rates. Similarly, the spatial density distribution of tumor cells is assumed
to exponentially decay with x and proportional to exp(−x/τc), where τc is the characteristic length
scale of decrease in cell density. Panel (b) plots the spatial drug gradient mediated by the tumor
microenvironment [23]: D(x) = D0 exp(−x/τD), where D0 is the maximum possible concentration
in the center and τD is the characteristic length scale of spatial decay of drug concentrations with
respect to the distance to the blood vessel, x. Panels (c) and (d) show the escape probability and
the average time to resistance (conditional relapse time to acquisition of two point mutations) as a
function of the level of spatial drug heterogeneity, 1/τD. Using a series of consecutive concentric cir-
cles with equal interval in between, we artificially divide the tumor into M compartments (similar to
contour lines shown in b). Cells in the same compartment are regarded as homogeneous subpopula-
tions. Tumor cells can migrate to the two nearest neighbouring compartments with equal probability
v/2. Acquisition of two point mutations is needed to survive in the centre with the maximum drug
concentration, D0. Parameters: tumor size N = 1011, τg = τc = 1cm, D0 = 500, b0 = 0.5, d0 = 0.4,
M = 30, n = 3, IC50 = 50, m = 2, s = 0.01, ρ = 5, u = 10−9, v = 2 × 10−4.
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Supporting Information Legends:
Figure S1 Spatio-temporal snapshots of emerging drug resistance. Panels (a) - (d) plot the joint prob-
ability density distribution of the numbers of resistant cells in both compartments at time points
t = 10, 50, 100, 200, respectively, starting with a single sensitive cell placed in the sanctuary com-
partment. Parameters are the same as in Fig. 3.
Figure S2 The average time to resistance as a function of the size of lesion 1, rescaled by the mutation
rate, uN1. Relapse occurs sooner with bigger tumor size at the start of therapy. Relapse is destined to
happen in the presence of drug sanctuary and cell motility. The situation is even worse for really big
tumor sizes at the start of therapy; relapse can happen within weeks. Parameters: D0 = 0, D1 = 100,
v = 10−4, and other parameters are the same as in Fig. 4.
Figure S3 Optimal migration rate. Parameters: D0 = 0, D1 = 100, and other parameters are the same as in
Fig. 4.
Figure S4 The relapse time depends on the number of point mutations that is needed to confer sufficient
levels of resistance to increasingly high drug concentrations. (a) shows the escape probability as
a function of the difference in drug concentrations between the two metastatic compartments, ∆D.
(b) shows how the average time to resistance changes with increasing ∆D. The vertical line marks
the critical value of ∆D above which two point mutations are required to confer sufficient levels of
resistance to increasingly high concentrations in compartment 1 while compartment 0 is the sanctuary
containing lower level of drugs. Parameters: ρ = 3.5, v = 10−4, and other parameters are the same as
in Fig. 4.
Figure S5 The role of cell motility in the emergence of full resistance under local and global migrations.
Shown are the escape probabilities and the average conditional time to resistance for a single sensitive
cell initially placed in each compartment, with increasing migration rate, v. The spatial heterogeneity
in drug concentrations is realized by using a rescaled Normal distribution with a peak in the central
compartment, and the level of heterogeneity is denoted by the standard deviation, σ, of the concen-
tration distribution over compartments. Parameters: M = 20, n = 5, IC50 = 100, m = 2, ρ = 1.1,
¯D = 50, s = 0.01, b0 = 0.2, d0 = 0.1, µ = 10−4, σ = 24.7.
Figure S6 The impact of the spatial heterogeneity in drug concentrations on the emergence of full re-
sistance under local and global migrations. Shown are the escape probabilities and the average
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conditional time to resistance for a single sensitive cell initially placed in each compartment, with
increasing spatial heterogeneity, σ. The spatial heterogeneity in drug concentrations is realized by
using a rescaled Normal distribution with a peak in the central compartment, and the level of hetero-
geneity is denoted by the standard deviation, σ, of the concentration distribution over compartments.
Parameters: M = 20, n = 5, IC50 = 100, m = 2, ρ = 1.1, ¯D = 50, s = 0.01, b0 = 0.2, d0 = 0.1,
µ = 10−4, v = 0.01.
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Appendix A: Full model
For completeness, here we present in details the model description and the analytical methods. In this
paper, we use a simple spatial model to study the evolution of resistance to cancer therapy, particularly in the
presence of sanctuary sites with low or no drug concentration. Our approach is based on branching process
theory. The present study focuses only on (single-) drug resistance arising during treatment, rather than pre-
existing resistance prior to treatment. When cancer patients with metastatic diseases are administered potent
drugs, it is often the case that the drug is not uniformly distributed throughout the body compartments of
the cancer patient due to various factors such as drug penetration problems. This leads to non-homogeneous
drug concentrations across different body compartments, which may harbor small metastatic populations.
These compartments with low drug concentrations, which are insufficient to fully inhibit the replication of
cancer cells, become the sanctuaries from which drug resistant mutants can emerge. Through migration
these resistant mutants can subsequently populate compartments with high drug concentration, where the
sensitive type cannot survive. By such intuitive reasoning, we hypothesize that the spatial heterogeneity
in drug concentrations can speed up the evolution of acquired resistance to cancer therapy. In the rest of
this supplementary information, we shall derive mathematical results to investigate this hypothesis. Our
theoretical results shed new light onto the emergence of drug resistance and treatment failure of cancer
patients with metastatic diseases.
Let us consider a spatial compartment model of metastatic diseases. There are M compartments in total
and the drug concentration in each compartment i is denoted by Di. We restrict our analysis on spatially
heterogeneous drug concentrations, but without time-changing concentration fluctuations. Metastatic cancer
cells have already acquired motility and are assumed to migrate between compartments with rate v. The
effect of the drug can either be cytostatic inhibiting cell growth and division or be cytotoxic killing cells
directly, or both. Without loss of generality, we assume here that the drug inhibits cell growth. Reproduction
is subject to mutation. Upon division, one of the two daughter cells mutates with rate u. By acquiring step-
wise point mutations, the mutant becomes more and more adapted to drug environments and can eventually
survive in high-concentration compartments. Denote by i the genotype of a cancer cell if it has acquired i
point mutations. The replication rate of a cancer cell, bi j, is determined by its genotype i and spatial location
j as follows,
bi j = β j
1 − is
1 +
[ D j
ρiIC50
]m . (A1)
Here we use a Hill function for the drug response curve. β j is the division rate of a wild type cell in
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compartment j in the absence of drug, s is the cost of mutation in the absence of drug, IC50 is the drug
concentration that is needed to inhibit cell growth by one half of its original rate, ρ is the fold increase in
IC50 per mutation, and m determines the steepness of the Hill function. We note that drug mutations are
deleterious in the absence of drugs. Thus the replication rate of a mutant with genotype i and in compartment
j is (1 − is)β j in the absence of drugs, whereas its IC50 is increased to ρiIC50 in the presence of drugs.
Throughout this supplementary information, unless stated otherwise, the death rate of a cancer cell with
genotype i within compartment j, di j, is all the same across compartment and equal to that of the wild type
in the absence of drugs, di j = α j = d0.
The migration pathway is specified by the underlying connections between compartments. For sim-
plicity, we consider two different schemes of migration: local migration versus global migration. Local
migration means that compartments are situated on a “ring” where a cancer cell can only migrate to the two
nearest neighbor compartments with equal probability v/2. In contrast, global migration means compart-
ments are fully connected where a cancer cell is allowed to migrate from one compartment to any other one
with equal probability v/(M − 1). We restrict our subsequent analysis to these two foregoing migration pat-
terns, though it is straightforward to extend it to more complicated migration patterns in our mathematical
model.
In what follows, we shall use a continuous-time multi-type branching process to describe resistance
evolution.
Appendix B: Analysis
As for multi-type branching process, we first need to construct the appropriate type space using the
combination of genotype gi ∈ {0, 1, · · · , n − 1} and compartment location l j ∈ {0, 1, · · · , M − 1}. Thus a
cell’s type can be denoted by two-bit strings gil j ∈ {0, 1, · · · , n−1}×{0, 1, · · · , M−1} and thus there are n×M
different types. For example, a cell with “11”-type means that this cell has accumulated 1 point mutation
and is located in compartment 1. Therefore, a cell’s type, notated by its genotype and spatial location, can
change as results of genetic mutation or migration.
Next let us introduce the probability generating functions. Denote by Fi j(X; t) the probability generating
function for the lineages at time t initiated by a single i j-type cell, where X = [x00, . . . , xn−1,M−1] denotes
the vector of dummy variables with elements xi j representing each i j-type of cells. During an infinitesimal
time interval ∆t, with probability bi j(1 − u)∆t an i j-type cell gives birth to two identical daughter cells,
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with probability bi ju∆t it gives rise to an identical offspring and a mutated offspring, with probability v∆t
it migrates to another compartment, with probability di j∆t it dies, and with probability 1 − (bi j + di j + v)∆t
nothing changes. We can use the probability generating function approach to account for what can happen
to an i j-type cell during an infinitesimal time interval ∆t,
fi j(X;∆t) = di j + bi j(1 − u)∆tx2i j + bi ju∆txi j x(i+1) j +
v
M − 1∆t
∑
k, j
xik + [1 − (bi j + di j + v)∆t]xi j. (B1)
Using the multiplicative property of branching process (the independency of each individual lineage), the
generating function Fi j(X; t + ∆t) satisfies the recursive backward equation,
Fi j(X; t + ∆t) = fi j(F;∆t), (B2)
where F is the vector of the probability generating functions with elements Fi j(X; t). We obtain the follow-
ing backward equation for global migration (0 ≤ i < n − 1, 0 ≤ j ≤ M − 1).
∂Fi j(X; t)
∂t
= lim
∆t→0
fi j(F(t);∆t) − Fi j(X; t)
∆t
= di j + bi j(1 − u)F2i j + bi juFi jF(i+1) j +
v
M − 1
∑
k, j
Fik − (bi j + di j + v)Fi j. (B3)
Since we do not consider more than i = n − 1 point mutations, for i = n − 1 we have
∂Fi j(X; t)
∂t
= di j + bi jF2i j +
v
M − 1
∑
k, j
Fik − (bi j + di j + v)Fi j. (B4)
The initial condition for these ODE’s is Fi j(X; 0) = xi j for i = 0, . . . , n − 1 and j = 0, . . . , M − 1. For any
given profile of the initial numbers of cells, N = {Ni j}, the corresponding probability generating function
FN is a power compound of Fi j
FN =
∏
i, j
Fi j(X; t)Ni j . (B5)
Analogously with Eq. (B3), we can derive the backward equation for local migration,
∂Fi j(X; t)
∂t
= di j + bi j(1 − u)F2i j + bi juFi jF(i+1) j +
v
2
Fi[( j−1+M)%M] +
v
2
Fi[( j+1)%M] − (bi j + di j + v)Fi j. (B6)
In the above equation, the subscripts [( j − 1 + M)%M] and [( j + 1)%M] account for the two neighbor
compartments the cell may migrate to.
In the following unless stated otherwise, we have di j = d0 for all types of cells, while bi j depends on
the drug concentration in compartment j as in Eq. (A1). The fate of a i j-type cell can either go extinct in a
relatively short time or successfully establish surviving lineages with expanding populations. The extinction
probability, which is the opposite of escape probability, can be obtained by solving the fixed points of the
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ODE’s given above. We can also calculate the probability that there is no evolved fully resistant strain in
any compartment by time t, conditional on non-extinction.
For arbitrary number of genotypes and arbitrary number of compartments, we cannot find closed form
probability generating functions for these nonlinear ODE’s. To circumvent this difficulty, we rely on numer-
ical ODE solvers to obtain the quantities of interest. For instance, if we solve the above nonlinear ODE’s
with the initial condition xi j = 0, we can obtain the extinction probability Fi j(0; t) for each i j-type cell at
time t. For t → ∞, Fi j(0; t) converges to the steady equilibrium value (i.e., the smallest of all admissible
fixed points). Using the initial condition XnoR = [xi j] where xi j = 1 for i < n − 1 and xi j = 0 for i = n − 1,
the conditional probability PnoR(t) that there is no evolved fully resistant strain in any compartment by time
t, starting with an i j-type cell, can be calculated as,
PnoR(t) =
Fi j(XnoR; t) − Fi j(0;∞)
1 − Fi j(0;∞) . (B7)
In general, for any given profile of the initial numbers of cells, N = {Ni j}, the extinction probability
PE(t) at time t is given by
PE(t) =
∏
i, j
Fi j(0; t)Ni j . (B8)
The conditional probability PnoR(t) is given by
PnoR(t) =
∏
i, j Fi j(XnoR; t)Ni j −
∏
i, j Fi j(0;∞)Ni j
1 −∏i, j Fi j(0;∞)Ni j . (B9)
1. Simple model
For the simple model with 2 genotypes and 2 compartments, we are able to derive closed-form approxi-
mations for special cases. The backward equations are as follows,
∂F00
∂t
= d00 + b00(1 − u)F200 + b00uF00F10 + vF01 − (d00 + b00 + v)F00
∂F01
∂t
= d01 + b01(1 − u)F201 + b01uF01F11 + vF00 − (d01 + b01 + v)F01
∂F10
∂t
= d10 + b10F210 + vF11 − (d10 + b10 + v)F10
∂F11
∂t
= d11 + b11F211 + vF10 − (d11 + b11 + v)F11. (B10)
These are coupled nonlinear Riccati equations, for which we do not have closed-form explicit solutions.
For simplicity, let us further assume dichotomous drug environments: compartment 0 is drug free, while
compartment 1 is distributed with a drug that inhibits cell growth. We have di j = d0. In the drug-free
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compartment 0, both sensitive and resistant cells have supercritical replication potential in drug free com-
partment, but resistant cells have slightly lower replication rates than sensitive type due to the cost of the
resistant mutation. We have b00 > d00, b10 > d10, and b10 < b00. In the drug-containing compartment 1,
sensitive cells have a subcritical replication potential while resistant cells still have a supercritical replication
potential. We have b01 < d01, b11 > d11, and b11 > b01.
For such a fitness landscape, the drug-free compartment provides far more favorable condition for breed-
ing resistance than the drug-containing compartment. Therefore, the likely origin for treatment failure, these
resistant cells that populate the drug-present compartment, should be attributed to the “mutation-migration”
pathway than the “migration-mutation” pathway. In other words, it is less likely that resistance evolves
in situ in the drug-containing compartment than that resistance mutants are originated from the drug-free
compartment and then migrate to the drug-containing compartment.
2. Drug-environment-dependent escape
To verify these arguments above, let us first calculate and compare the likelihood of obtaining an escape
mutation within one separate compartment (without any migration at all). For simplicity, the compartment
is only seeded with a single sensitive cell. Denote by b0 and b1 the division rate of sensitive cells and
resistant ones in that compartment. The death rate of the two types of cells is the same, d0 = d1. We have
b0 > b1 > d0 for compartments with low concentrations, whereas b0 < d0 < b1 for compartments with
high concentrations. Let f 0(x, y, t) denote the probability generating function for the lineages starting with
a single sensitive cell, and let f 1(x, y, t) denote the probability generating function for the lineages starting
with a single resistant cell. We have the following differential equations:
d f 0
dt = d0 + b0(1 − u) f
0 f 0 + b0u f 0 f 1 − (b0 + d0) f 0, (B11)
d f 1
dt = d1 + b1 f
1 f 1 − (b1 + d1) f 1. (B12)
The initial condition is f 0(x, y, 0) = x and f 1(x, y, 0) = y.
a. b0 > b1 > d0
For sufficiently small mutation rates u ≪ 1, we can derive a closed form approximation to the equations
above. Let ri = bi − di denote the net growth rate of type-i cells, i = 0, 1. We have r0 > r1 > 0. Neglecting
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the loss of sensitive cells due to rare mutations, we have
d f 0(x, t)
dt = d0 + b0 f
0 f 0 − (b0 + d0) f 0. (B13)
This ODE above is explicitly soluble, and we obtain:
f 0(x, t) = b0x − d0 − d0(x − 1)e
r0t
b0x − d0 − b0(x − 1)er0t . (B14)
Denote by X0(t) the number of sensitive cells at time t. Previous results show that X0(t)e−r0t is a non-negative
martingale and X0(t)e−r0t → W0 for t → ∞. The Laplace transform of W0 is given by
Ee−θW0 = E
(
e−θe
−r0 t)X0
= f 0(e−θe−r0 t , t). (B15)
For t → ∞, using e−θe−r0 t − 1 ≈ −θe−r0t, we obtain
Ee−θW0 ≈ r0 + d0θ
r0 + b0θ
=
d0
b0
+ (1 − d0b0 )
1
1 + b0
r0
θ
. (B16)
Accordingly, we obtain the limiting distribution of W0 for t →∞ as follows.
W0 =
d0
b0
δ0 + (1 − d0b0 )Exponential(
r0
b0
), (B17)
where δ0 is a point mass at zero (corresponding to extinction), and Exponential( r0b0 ) is an exponential dis-
tribution with the exponent r0b0 . It is easy to see that, conditional on non-extinction, X0(t)e−r0t → V0 =
Exponential( r0b0 ). Thus the Laplace transform of V0 is
Ee−θV0 =
1
1 + b0
r0
θ
. (B18)
The rate at which resistant mutants arise is ub0X0(t). Hence the conditional probability that the arrival
time of the first mutant τ1 > t is
P(τ1 > t|X0(t) > 0) = Ee−
∫ t
0 ub0V0e
r0 sds
=
1
1 + ub
2
0
r20
(er0t − 1)
≈ 1
1 + ub
2
0
r20
er0t
. (B19)
The median arrival time
t 1
2
=
log(r20/ub20)
r0
.
We can see that t 1
2
is monotonically decreasing with increasing b0 (u ≪ 1). That is, the less harsh the
compartment is (b0 ↑), the sooner resistant mutants arise (t 1
2
↓). In this sense, compartments with lower
drug concentrations are more likely the breeding ground for resistance, since the replication of sensitive
cells is less affected than in compartments with higher drug concentrations.
For small mutation rate u ≪ 1, the escape probability P1 that a single sensitive cell establishes lineages
without going extinction is approximately
P1 ≈
r0
b0
− ud0(b0d1 − b1d0)b0b1r0 . (B20)
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b. b0 < d0 < b1
In this unfavorable case, sensitive cells do not have a chance to survive but resistant cells do. The approx-
imation method used above does not work here, since the branching process of sensitive cells is subcritical.
To establish surviving lineages, sensitive cells must evolve resistant mutation right before quickly dying
out. We cannot find a closed form for the arrival time of the first mutant for this case, but it is easy to see
that if the mutant does arise (though with a lower chance), it takes much longer time due to the smaller birth
rate than in benign environments. The escape probability of a single sensitive cell is approximately
P1 ≈ −u
b0r1
b1r0
, (B21)
which is much smaller than Eq.(B20). Moreover, we should note that the escape probability P1 is of the
order
√
u if sensitive cells are almost critical |r0| → 0:
P1 ≈
√
u
r1
b1
. (B22)
3. Competing pathways to the emergence of resistance
Returning to the simple model introduced above, we are now primarily concerned with which path-
way leads faster to resistant cells that populate the drug-present compartment. To this end, we compare
two distinct pathways. The migration-mutation pathway: sensitive cells first migrate from the drug-free
compartment to the drug-present compartment, and then acquire resistance in situ. The mutation-migration
pathway: sensitive cells acquire resistant mutation in the drug-free compartment, followed by migration to
the drug-present compartment.
As shown above, we cannot obtain closed-from solutions for this four-type branching process. To sim-
plify our mathematical derivations, let us consider unidirectional emigration flow only from the drug-free
compartment to the drug-present compartment. To compare which pathway is faster, let us further artifi-
cially separate these two pathways, making only one pathway at work at a time, instead of considering them
simultaneously. In this way, each pathway can seen as a three-type branching process:
type 0
µ0−→ type 1 µ1−→ type 2.
For the migration-mutation pathway, µ0 = v and µ1 = ub01; for the mutation-migration pathway, µ0 = ub00
and µ1 = v. The difference of the fitness landscape between these two pathways lies in the intermediate type
1, namely, the division rate b01 of sensitive cells in the drug-present compartment versus the division rate
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b10 of resistant cells in the drug-free compartment. It is therefore useful to first study a general three-type
branching process and then obtain the results for each pathway by substituting the specific fitness landscape
for each pathway.
For rare mutations (u ≪ 1) and low migration rates (v ≪ 1), we are able to derive explicit closed-form
approximations for the conditional probability of no type 2 cells by time t. Let bi and di be the birth and
death rate of type i cells, i = 0, 1, 2. Let ri = bi − di be the net growth rate of type i cells. We have r0 > 0,
r2 > 0, and r1 < r0. Conditional on non-extinction, the number of type 0 cells at time t is given by
X0(t) = V0er0t (B23)
Because type 1 is less fit than type 0 (r1 < r0), we can approximate the number of type 1 cells at time t as
X1(t) = µ0
∫ t
0
V0er0 ser1(t−s)ds = µ0V0
er0t[1 − e(r1−r0)t]
r0 − r1
∼ µ0V0
er0t
r0 − r1
, (B24)
where x(t) ∼ y(t) means x(t)/y(t) → 1 for large t.
The conditional probability that there are no surviving type 2 cells by time t is
P(X2(t) = 0|X0(t) > 0) = E exp[−µ1
∫ t
0
X1(s) r2b2 − d2e−r2(t−s)
ds]
= E exp[−µ0µ1V0
∫ t
0
er0s
r0 − r1
r2
b2 − d2e−r2(t−s)
ds]
=
1
1 + θ2(t)b0r0
, (B25)
where the integral θ2(t) = µ0µ1 r2r0−r1
∫ t
0
er0 s
b2−d2e−r2(t−s) ds.
Substituting the fitness landscape of each pathway, we find a simple condition for the mutation-migration
pathway faster than the migration-mutation pathway in leading to surviving resistant cells in the drug-
containing compartment if the follow inequality holds:
b00
b00 − d00 − (b10 − d10) >
b01
b00 − d00 − (b01 − d01) . (B26)
Concerning cytostatic drugs that inhibits cell division, we have d00 = d10 = d01 = d11 = d0, b00 = b0,
b10 = (1 − s)b0 and b01 = (1 − δ)b0. s denotes the fitness cost of resistant mutation in the absence of drugs,
and δ denotes the fitness cost of sensitive cells in the presence of drugs. Then the above condition simplifies
to
δ >
s
1 + s
. (B27)
For cells in compartments with potent drugs and with sufficiently high drug concentrations, we have δ > s.
More generally, the emergence of resistance is more contingent on the mutation-migration pathway than the
migration-mutation pathway, if the difference of drug concentration between two neighboring compartments
leads to the landscape satisfying the inequality (B26).
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Appendix C: Numerical results
In what follows, we report the numerical results on the full model. To avoid boundary problems, we
consider generic, symmetric spatial distributions of drug concentrations over compartments, according to
a rescaled Normal distribution such that the degree of heterogeneity can be tuned by the variance of the
distribution while keeping the total sum of concentrations constant. We compare the extinction probabilities
and the time to resistance for sensitive cells initially located in each compartment, with varying migration
rate and the spatial heterogeneity in drug concentrations.
The results are consistent with those reported in the main text (FigS. 5 and 6). Sanctuary sites are com-
partments with low drug concentration, which are responsible for producing the resistance that populates
compartments with high drug concentration. Selection for resistance is more contingent on the mutation-
migration pathway than the migration-mutation pathway, particularly in the presence of sanctuary sites.
Moreover, only for small migration rates below a certain threshold does the spatial heterogeneity in drug
concentrations help speed up the resistance evolution. However, excessively high migration rates actually
slow down resistance emergence, as the role of compartment structure is diminished by frequent migration.
Furthermore, we observe interesting results when comparing local migration to global migration. Both
the extinction probability and the time to resistance depend more sensitively on migration rate for global
migration than for local migration (FigS. 5). This is because global migration favors the dissemination
of resistance all over the place, whereas local migration constrains the migration within neighboring com-
partments with reduced drug difference such that accruing one point mutation is sufficient to offset the
increasing drug concentration. As a consequence, resistance evolves much faster for local migration than
global migration, particularly for sensitive cells located at the sanctuary sites with low drug concentrations.
On the contrary, the escape probability of sensitive cells located in the compartments with high concentra-
tions is hampered more by local migration than by global migration. In this case, local migration limits its
dispersal range, while global migration increases the chance of moving to sanctuary sites thus leading to
greater escape probabilities. More specifically, compared to global migration, local migration speeds up the
evolution of resistance for sensitive cells initially located at sanctuary sites, while delaying the evolution of
resistance for sensitive cells initially located at harsh compartments with high levels of drugs. Regarding
the latter case, moreover, there exists an optimal intermediate global migration rate with which the time to
resistance is minimal.
Sanctuary sites for sensitive cells result when varying from homogeneous drug distributions to increas-
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ingly heterogeneous drug concentrations across spatial compartments. It is obvious that compartments with
low concentrations become the shelter for sensitive cells and thus provide benign condition for breeding
resistance that can be selected for in compartments with excessively high concentrations (FigS. 6). Local
migration takes less time to evolve resistance than global migration, if these cells are initially located at the
sanctuaries. Opposite results are obtained if these cells are initially located at harsh compartments. Un-
der local migration, there exists an optimal level of heterogeneity in drug concentrations that most delays
the emergence of resistance. In contrast, increasing the spatial heterogeneity in drug concentrations helps
prolong the time to resistance under global migration.
Altogether, these results confirm that our conclusions derived from the simple model in the main text
are robust with respect to model extensions and varying model parameters. In addition, the scheme of
migration plays an important role in the evolution of acquired resistance. However, future studies are
needed in order to characterize, and eventually manipulate, the migration routes for metastatic cells. We
think that constraining escape route of metastatic cells to sanctuary sites and limiting dissemination of
evolved metastatic cells from sanctuary sites are vital to eliminate disseminated cancer.
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